Amgen AMGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.8B+31.5% | $7.71B+88.5% | $7.01B+65.6% | $6.62B+111% | $5.93B+57.7% | ||
| $4.9B-12.3% | $5.17B-7.6% | $5.43B-2.6% | $5.52B+8.8% | $5.58B+22.1% | ||
| $484M-5.5% | $494M-6.8% | $503M-9.7% | $512M-2.5% | $512M+5.1% | ||
| -$647M+39.9% | -$721M+41.3% | -$1.04B+31.7% | -$1.12B+39.8% | -$1.08B+33.7% | ||
| —— | —— | —— | —— | $891M— | ||
| $1.18B— | $2.9B— | $1.35B— | $1.69B— | —— | ||
| -$616M+69.4% | -$886M+65.0% | -$1.09B+60.8% | -$1.53B+25.2% | -$2.01B-48.6% | ||
| —— | —— | —— | —— | —— | ||
| $414M+52.2% | $499M+442% | $478M+92.7% | $403M— | $272M— | ||
| $1.06B+38.5% | $1.27B+94.3% | $704M-19.1% | $720M-13.7% | $764M— | ||
| -$161M— | -$164M— | —— | —— | —— | ||
| -$132M— | -$149M— | $139M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.65B— | ||
| $10.76B-11.8% | $9.96B-13.3% | $13.13B+80.9% | $12.01B+86.4% | $12.19B+50.6% | ||
| $2.16B+69.1% | $1.86B+69.5% | $1.59B+62.9% | $1.41B+45.9% | $1.28B+28.0% | ||
| —— | —— | —— | —— | —— | ||
| -$2.21B-73.4% | -$1.94B-85.8% | -$1.65B+94.0% | -$1.45B— | -$1.28B— | ||
| $5.2B+6.1% | $5.12B+6.0% | $5.05B+5.9% | $4.97B+5.9% | $4.9B+6.0% | ||
| —— | —— | —— | —— | $0-100% | ||
| $3.33B-45.4% | $5B+38.9% | $5B— | $5.7B— | $6.1B— | ||
| —— | —— | —— | -$121M— | -$69M— | ||
| -$5.32B+55.0% | -$10.86B-15.3% | -$11.04B-110% | -$11.84B— | -$11.81B— | ||
| —— | —— | —— | -$1.27B— | -$898M— | ||
| —— | —— | $2.96B+180% | $2.7B+632% | $2B+95.5% | ||
| $312M— | $311M— | —— | —— | —— | ||
| $1.06B+38.5% | $1.27B+94.3% | $704M-19.1% | $720M-13.7% | $764M— | ||
| -$132M— | -$149M— | $139M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $615M— | $683M— | —— | —— | —— | ||
| —— | —— | —— | -$121M— | -$69M— | ||
| —— | —— | —— | —— | $1.65B— | ||
| $8.6B-21.2% | $8.1B-22.1% | $11.54B+83.7% | $10.61B+93.5% | $10.92B+53.8% | ||
| $8.6B-21.2% | $8.1B-22.1% | $11.54B+83.7% | $10.61B+93.5% | $10.92B+53.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amgen generate?
- Amgen (AMGN) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Amgen's free cash flow?
- After $2.2B of capital expenditures, Amgen's free cash flow was $8.6B over the trailing twelve months, down 21.2% year over year.
- Where does Amgen's cash flow data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
